Dimerization of HIV protease is essential for the acquisition of protease's proteolytic activity. We previously identified a group of HIV protease dimerization inhibitors, including darunavir (DRV). In the present work, we examine whether loss of DRV's protease dimerization inhibition activity is associated with HIV development of DRV resistance. Single amino acid substitutions, including I3A, L5A, R8A/Q, L24A, T26A, D29N, R87K, T96A, L97A, and F99A, disrupted protease dimerization, as examined using an intermolecular fluorescence resonance energy transfer ( 
Dimerization of HIV protease is essential for the acquisition of protease's proteolytic activity. We previously identified a group of HIV protease dimerization inhibitors, including darunavir (DRV). In the present work, we examine whether loss of DRV's protease dimerization inhibition activity is associated with HIV development of DRV resistance. Single amino acid substitutions, including I3A, L5A, R8A/Q, L24A, T26A, D29N, R87K, T96A, L97A, and F99A, disrupted protease dimerization, as examined using an intermolecular fluorescence resonance energy transfer (FRET)-based HIV expression assay. All recombinant HIV NL4-3 -based clones with such a protease dimerization-disrupting substitution failed to replicate. A highly DRV-resistant in vitroselected HIV variant and clinical HIV strains isolated from AIDS patients failing to respond to DRVcontaining antiviral regimens typically had the V32I, L33F, I54M, and I84V substitutions in common in protease. None of up to 3 of the 4 substitutions affected DRV's protease dimerization inhibition, which was significantly compromised by the four combined substitutions. Recombinant infectious clones containing up to 3 of the 4 substitutions remained sensitive to DRV, while a clonal HIV variant with all 4 substitutions proved highly resistant to DRV with a 205-fold 50% effective concentration (EC 50 ) difference compared to HIV NL4-3 . The present data suggest that the loss of DRV activity to inhibit protease dimerization represents a novel mechanism contributing to HIV resistance to DRV. The finding that 4 substitutions in PR are required for significant loss of DRV's protease dimerization inhibition should at least partially explain the reason DRV has a high genetic barrier against HIV's acquisition of DRV resistance.
Currently available combination therapy or highly active antiretroviral therapy (HAART) for human immunodeficiency virus type 1 (HIV) infection and AIDS has been shown to potently suppress the replication of HIV and extend the life expectancy of HIV-infected individuals (32, 34) . Recent analyses have revealed that life expectancy in HIV-infected patients treated with HAART has significantly increased, that mortality rates for HIV-infected persons have recently become close to that of general population, and that the appearance of the current first-line antiretroviral therapy with boosted protease inhibitor (PI)-based regimens has made the development of HIV resistance relatively less likely (2, 7, 18, 39) . However, the ability to provide effective long-term antiretroviral therapy for HIV infection remains a complex issue since many of those who initially achieved favorable viral suppression to undetectable levels still suffer treatment failure (12, 18, 29) .
Dimerization of HIV protease (PR) subunits is an essential process for the acquisition of proteolytic activity of HIV PR, which plays a critical role in the maturation and replication of the virus (28, 40) . Thus, inhibition of PR dimerization by chemical reagents is likely to abolish proteolytic activity and intervene in HIV replication. We have recently developed an intermolecular fluorescence resonance energy transfer (FRET)-based HIV-expression assay that employs cyan fluorescent protein (CFP)-and yellow fluorescent protein (YFP)-tagged HIV PR monomers to detect and quantify PR dimerization (26) . Using this assay, we identified a group of nonpeptidyl small molecule inhibitors of HIV PR dimerization. These inhibitors, including darunavir (DRV) and tipranavir (TPV) as well as a series of potent experimental antiretroviral agents such as TMC126 (41) , blocked PR dimerization at concentrations of as low as 0.01 M and potently blocked HIV replication in vitro (26) . DRV contains a structure-based and designed privileged nonpeptidic P2 ligand, 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF) (14, 15, 27) , which potently inhibits the enzymatic activity and dimerization of HIV PR (26) and has a high-level genetic barrier against HIV development of resistance to DRV (9, 10) . Nevertheless, we have witnessed that HIV acquires significant levels of resistance against DRV among HIV-infected individuals who have received long-term combi-nation chemotherapy (33, 38) . Indeed, a variety of amino acid substitutions that are potentially related to HIV resistance to DRV have been reported (9, 24, 33, 38) . Thus, the elucidation of the mechanism of the development of HIV drug resistance represents an urgent subject in the research area of HIV-1 infection/AIDS and therapy.
MATERIALS AND METHODS
Cells, viruses, and antiviral agents. MT-4 cells were grown in RPMI 1640-based culture medium, and 293T and COS7 cells were propagated in Dulbecco's modified Eagle's medium. These media were supplemented with 10% fetal calf serum (FCS; PAA Laboratories GmbH, Linz, Austria) plus 50 U of penicillin and 50 g of kanamycin per ml. The following HIV strains were used for the determination of 50% effective concentrations (EC 50 s) against DRV and to construct plasmids for use in the FRET-based HIV expression assay, including HIV NL4-3 and HIV 8MIX
P51
. Three recombinant clinical HIV isolates ( rCL HIV F16 , rCL HIV T45 , and rCL HIV T48 ) used in this study were produced using recombinant HIV NL4-3 -based infectious molecular clones generated by ligating patient-derived amplicons encompassing approximately 200 nucleotides of 3Ј Gag (beginning at the unique ApaI restriction site), the entire protease, and the first 72 nucleotides of reverse transcriptase (RT) using the expression vector pNLPFB (a generous gift from Tomozumi Imamichi of the National Institute of Infectious Diseases and Allergy). The four clinical HIV isolates examined in the present study were chosen from 32 isolates that had been obtained from multi-PI-treated patients whose protease genotype contained prototypical patterns of PI resistance. The median duration of continuous PI treatment was 7.5 years (range, 6 to 10 years). The median number of PIs received (excluding the use of ritonavir for pharmacokinetic boosting) was 5 (range, 4 to 8). According to the PhenoSense assay, two isolates ( rCL HIV T45 and rCL HIV F16 ) had high-level resistance to all PIs, including Ͼ90-fold decreased susceptibility to DRV and Ͼ8-fold decreased susceptibility to TPV, and one isolate ( rCL HIV T48 ) had intermediate resistance to DRV and TPV and high-level resistance to the remaining PIs (see Table 2 ).
DRV was synthesized by A. K. Ghosh as described previously (16, 27) . GRL-0216 (37), GRL-98065 (1), and TMC-126 (41) were synthesized in a convergent manner by coupling an optically active P2 ligand and an (R)-hydroxyethylamino sulfonamide isostere (17) . TPV was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health.
Generation of FRET-based HIV expression system. Cyan fluorescent protein (CFP)-and yellow fluorescent protein (YFP)-tagged HIV PR constructs were generated using BD Creator DNA cloning kits (BD Biosciences, San Jose, CA). The basic concepts of the intermolecular FRET-based HIV expression assay (FRET-HIV assay) are illustrated in Fig. 1 . In brief, XhoI and HindIII fragments from the pCR-XL-TOPO vector containing the HIV PR-encoding gene excised from pHIV NL4-3 were inserted into pDNR-1r, the donor vector, which had been digested with XhoI and HindIII. In the transfer of the PR gene from the donor vector into pLP-CFP/YFP-C1 (acceptor vector), the Cre-loxP site-specific recombination method was used according to the manufacturer's instructions. Using Cre-recombinase with the loxP site, the PR gene from pDNR-1r was inserted into pLP-CFP-C1 or pLP-YFP-C1 through Cre-mediated recombination (19) , generating a plasmid expressing CFP-tagged wild-type PR (PR WT ) and one expressing YFP-tagged PR WT , with which HIV PR was successfully expressed as a fusion protein with CFP and YFP tagged at the C terminus, respectively. Western blot assay using anti-green fluorescent protein-specific rabbit polyclonal antibodies revealed that PR was correctly tagged with CFP or YFP (26) .
For the generation of full-length molecular infectious clones containing CFPor YFP-tagged PR, the PCR-mediated recombination (PMR) method was used (11) . To this end, we amplified an upstream proviral DNA fragment containing an ApaI site and HIV PR (excised from pHIV NL4-3 ) with primer pair Apa-PRO-F (5Ј-TTG CAG GGC CCC TAG GAA AAA GG-3Ј) plus PR-5Ala-R (5Ј-GGC TGC TGC GGC AGC AAA ATT TAA AGT GCA GCC AAT CT-3Ј), a middle proviral DNA fragment containing CFP (excised from pCFP-C1) or YFP (excised from pYFP-C1) (Clontech, Mountain View, CA) with primer pair CFPYFP-5Ala-F (5Ј-GCT GCC GCA GCA GCC GTG AGC AAG GGC GAG GAG CTG-3Ј) plus CFPYFP-FP-R (5Ј-ACT AAT GGG AAA CTT GTA CAG CTC GTC CAT GCC G-3Ј), and a downstream proviral DNA fragment containing the 5Ј-DNA fragment of RT and an SmaI site from pHIV NLSma (13, 25) , which had been created to have an SmaI site by changing two nucleotides (2590 and 2593) of pHIV was also introduced between the fluorescent protein and RT. Thus, the three DNA fragments obtained were subsequently joined by using the PMR reaction performed under the standard condition for ExTaq polymerase (Takara Bio, Inc., Otsu, Japan) with 10 pmol of Apa-PRO-F (5Ј-TTG CAG GGC CCC TAG GAA AAA GG-3Ј) and NL4-3-RT263-R (5Ј-CCA GAA ATC TTG AGT TCT CTT ATT-3Ј) and the three DNA fragments (100 ng each) in a 20-l reaction solution. Thermal cycling was carried out at 94°C for 3 min, followed by 35 cycles of 94°C for 50 s, 53°C for 50 s, and 72°C for 2 min, and finally 72°C for 15 min. The amplified PCR products were cloned into pCR-XL-TOPO vector according to the manufacturer's instructions (Gateway cloning system; Invitrogen). PCR products were generated with pCR-XL-TOPO vector as templates, followed by digestion by both ApaI and SmaI, and the ApaI-SmaI fragment was introduced into pHIV NLSma (13) , generating pHIV-PR WT CFP and pHIV-PR WT YFP , respectively.
Analysis of inter-and intramolecular interactions of PR subunits. Analysis of inter-and intramolecular interactions of PR subunits was conducted by examining the crystal structure of DRV with HIV PR (Protein Data Bank identification no. [PDB ID no.] 2IEN). Hydrogens were added and minimized using the OPLS2005 force field with constraints on heavy atom positions. The calculation was performed using MacroModel 9.1 from Schrödinger, LLC. Hydrogen bonds were assigned when the following distance and angle cutoff was satisfied: 3.0 Å for H-A distance, with a D-H-A angle of Ͼ90°and an H-A-B angle of Ͼ60°, where H is the hydrogen, A is the acceptor, D is the donor, and B is a neighbor atom bonded to the acceptor. The representative distance between the termini of two monomers was determined by analyzing the PR-DRV crystal structure (PDB ID no. 2IEN). The distance between the ␣ carbons at the N termini and C termini is around 0.5 nm, whereas the distance between the ␣ carbons of the N termini ends of two monomers is around 1.8 nm.
FRET procedure. COS7 cells plated on an EZ view cover glass bottom culture plate (Iwaki, Tokyo) were transfected with the indicated plasmid constructs, using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions in the presence of various concentrations of each compound, cultured for 72 h, and analyzed under a Fluoview FV500 confocal laser scanning microscope (Olympus Optical Corp., Tokyo) at room temperature. When the effect of each compound was analyzed by FRET, test compounds were added to the culture medium simultaneously with plasmid transfection. The results of FRET were determined by quenching of CFP (donor) fluorescence and an increase in YFP (acceptor) fluorescence (sensitized emission), because part of the energy of CFP is transferred to YFP instead of being emitted. This phenomenon can be measured by bleaching YFP, which should result in an increase in CFP fluorescence. This technique, also known as acceptor photobleaching, is a well-established method of determining the occurrence of FRET (5, 6, 35, 36) . Dequenching of the donor CFP by selective photobleaching of the acceptor YFP was performed by first obtaining YFP and CFP images at the same focal plane, followed by illuminating the same image for 3 min at a wavelength of 488 nm with a laser power set at the maximum intensity to bleach YFP and then recapturing the same CFP and YFP images. The changes in the CFP and YFP fluorescence intensity in the images of selected regions were examined and quantified using the Olympus FV500 Image software system (Olympus Optical Corp.). Background values were obtained from the regions where no cells were present and were subtracted from the values for the cells examined in all calculations. For each chimeric protein, the data were obtained from at least three independent experiments. Digitized image data obtained from the experiment were prepared for presentation using Photoshop 6.0 (Adobe Systems, Mountain View, CA). Ratios of intensities of CFP fluorescence after photobleaching to CFP fluorescence prior to photobleaching (CFP A/B ratios) were determined. It is well established that CFP A/B ratios of Ͼ1.0 indicate that association of CFP-and YFP-tagged proteins occurred and were interpreted to indicate that the dimerization of PR subunits occurred. CFP A/B ratios of Ͻ1 indicated that the association of the two subunits did not occur and were interpreted to indicate that PR dimerization was inhibited. The difference in the CFP A/B ratios determined in the presence or absence of test drugs was evaluated using the nonparametric Mann-Whitney U statistic test.
Replication kinetics of various NL-PR mutant YFP strains. MT-4 cells (10 5 ) were exposed to each infectious HIV-PR YFP clone (100 ng of p24 Gag protein/ml) for 6 h, washed twice with phosphate-buffered saline (PBS), and cultured in 7 ml of complete medium with some modification as described previously (3, 13) . Culture supernatants (50 l) were harvested every other day, and virus replication was monitored by the amounts of p24 Gag produced in the culture supernatants.
RESULTS

DRV inhibits the dimerization of HIV PR expressed as a single protein.
The basic concepts of the intermolecular FRET-based HIV-expression assay (FRET-HIV expression assay) to assess PR dimerization are illustrated in Fig. 1 (26) . Using the FRETbased HIV expression assay, we previously identified a group of PR dimerization inhibitors (PDIs), including DRV and TPV, although other conventional PR inhibitors (PIs), such as amprenavir (APV), failed to block dimerization ( Fig. 2A) (26) . In the FRET-based HIV expression assay, YFP-or CFP-tagged PR should be primarily expressed as a part of Pr160 gag-pol polyprotein, and it was assumed that DRV blocks the dimerization of the PR subunit within the polyprotein. Thus, it remained to be determined whether DRV also blocks the dimerization of PR in the form of a single PR molecule. We, therefore, generated a pair of plasmids encoding wild-type HIV NL4-3 PR tagged with YFP and CFP in the 3Ј terminus (pPR WT YFP and pPR WT CFP , respectively), transfected COS7 cells with the pair, and determined whether DRV blocked the dimerization of PR WT YFP and PR WT CFP . As shown in A/B ratios were determined using an FV500 confocal laser microscope. When the average value of CFP A/B ratios was greater than 1.0, it was judged that the dimerization of PR occurred, whereas when it was less than 1.0, it was judged that the dimerization did not occur. (B) COS7 cells were cotransfected with a pair of wild-type PR-expressing plasmids (pPR WT CFP plus pPR WT YFP ) in the absence or presence of 1 M DRV or APV, and CFP A/B ratios were determined as described above. Note that DRV inhibited the dimerization of PR when it was expressed as HIV virions and virion-free PR. The results of statistical evaluation of the changes in the CFP A/B ratios, determined in the presence or absence of DRV or APV, using the nonparametric MannWhitney U test, are as follows. dimerization of PR WT YFP and PR WT CFP , while the value with APV was 1.17 Ϯ 0.27 (P ϭ 0.60), indicating that APV failed to block the dimerization, in line with our previous data (26) . These results strongly suggest that DRV blocks dimerization of the PR monomer subunit in the form of Pr160 gag-pol polyprotein as well as in the form of a single molecule.
Dimerization profiles of single PR mutants in the presence of DRV. Certain amino acids in the termini and active site interfaces, both of which are critical for the dimerization of PR monomer subunits (28, 40) , do not significantly affect the dimerization process of PR. Such amino acids include Pro-1, Gln-2, Thr-4, Asp-25, Ala-28, Asp-30, Thr-96, and Asn-98 (26) . It is assumed that DRV blocks PR dimerization by binding to a certain structural domain or domains within or in the proximity of either or both of the two interfaces (4, 22, 23) . We, therefore, examined whether amino acid substitutions at posi- 10 5 ) were exposed to the harvested supernatant of each infectious HIV-PR YFP clone shown in panel A (100 ng of p24 Gag protein/ml) for 6 h, washed twice with phosphate-buffered saline (PBS), and further cultured in 7 ml of complete medium. Culture supernatants (50 l) were harvested every other day, and virus replication was monitored by the amounts of p24 Gag produced in the culture supernatants. Replication kinetics of various HIV-PR YFP mutants are shown over 11 days. In subpanels a, b, and c, the replication kinetics of infectious clones carrying mutations in the active site, N ternimus, and C terminus, respectively, are shown. Note that recombinant HIV clones, whose replication rates were relatively poor, are illustrated in subpanel a. The experiments that generated data in subpanels a and b were performed on the same occasion. Thus, two controls (HIV-1 NL4-3sma and HIV-PR WT YFP ) in subpanel b serve as controls in subpanel a as well. (Fig. 3A) . These data suggest that all amino acid residues examined except A28S were not associated with the binding of DRV to the PR monomer subunit. We have previously shown that, in addition to DRV and TPV, the three compounds GRL-0216 (37), GRL-98065 (1), and TMC126 (41) effectively blocked PR dimerization in the FRET-based HIV expression assay (26) . Since the structures of these five compounds differ from each other, it was thought that the binding profiles of each compound also differed. We, therefore, examined if the four compounds other than DRV disrupted the dimerization of the A28S-carrying PR subunit. As shown in Fig. 3B , all four compounds failed to block protease dimerization, suggesting that Ala-28 is likely involved directly or indirectly in the binding of all four compounds to the PR monomer subunit.
Replication kinetics of HIV variants with failed PR dimerization. The failure of PR dimerization should completely block or significantly compromise the replication of HIV. In order to confirm that the observed dimerization failure elicited by a single amino acid substitution (26) causes replication failure of HIV, we generated a panel of HIV variants carrying YFPtagged PR with a single amino acid substitution and examined the replicative capability of each variant. When the amount of p24 antigen produced into culture medium following transfection of COS7 cells with each plasmid was quantified, an HIV variant containing I3A, L5A, L24A, D25A, T26A, A28S, D29N, R87K, T96A, L97A, or F99A produced no or a significantly small amount of p24 (Fig. 4A) . Among these variants, we have previously shown that I3A, L5A, T26A, D29N, R87K, T96A, L97A, and F99A disrupted PR dimerization (26) . Figure 5 shows that R8A (P ϭ 0.000099), R8Q (P ϭ 0.000084), and L24A (P ϭ 0.0000014) also disrupted PR dimerization, as examined in the FRET-based HIV expression assay (Fig. 5) . When fresh MT-4 cells were exposed to each cell-free culture supernatant of the transfected COS7 cells, as described above, no further replication was seen over the 11-day period of the culture (Fig. 4B) . The HIV variant carrying A28S also failed to replicate; however, this failure was explained by an observation that protease with A28S has almost no enzymatic activity, as reported by Hong et al. (20, 21) . In contrast, recombinant HIV clones containing either of P1A, Q2A, T4A, D30N, or N98A continued to replicate (Fig. 4B) .
DRV resistance profiles of PR species carrying DRV-resistance-associated amino acid substitutions. Using the standardized protocol for selection of drug-resistant HIV variants, we along with others have experienced difficulty in selecting DRVresistant HIV variants in vitro (8, 24) . The emergence of DRVresistant HIV variants was substantially slower than that of variants resistant to other FDA-approved PIs when a single HIV strain was employed as a starting viral strain (8, 24) . In this respect, we have recently succeeded in selecting a highly DRV-resistant HIV variant by using a mixture of 8 highly multi-PI-resistant, DRV-susceptible clinical HIV strains (HIV 8MIX strains HIV A , HIV B , HIV C , HIV G , HIV TM , HIV MM , HIV JSL , and HIV SS ), which were originally isolated from patients with AIDS, who had failed then-existing anti-HIV regimens after receiving 9 to 11 anti-HIV drugs over the previous 32 to 83 months in the late 1990s and contained 9 to 14 amino acid substitutions in the PR-encoding region (42) . By passage 39 in the selection with DRV, HIV 8MIX (HIV 8MIX P39 ) became highly resistant to DRV, with an EC 50 ϳ333-fold greater than that against HIV . HIV 8MIX at passage 39 (HIV 8MIX P39 ) was capable of replicating in the presence of 1 M DRV with a replication fitness comparable to that of HIV NL4-3 (24) . HIV 8MIX at passage 51 (HIV 8MIX P51 ), which was also capable of replicating in the presence of 5 M DRV, was found to contain the following 14 mutations: L10I, I15V, K20R, L24I, V32I, L33F, M36I, M46L, I54M, L63P, K70Q, V82I, I84V, and L89M (24) . As illustrated in Table 1, when HIV 8MIX P51 was propagated in the presence of 0.1 and 1.0 M DRV in CD4 ϩ MT-4 cells, the virus replicated comparably to HIV NL4-3 during the 9-day period of culture, while HIV NL4-3 completely failed to replicate in the presence of 0.1 or 1.0 M DRV, as examined according to the amounts of Gag protein produced in the culture supernatant, indicating that HIV 8MIX P51 had acquired a high-level resistance against DRV, while it maintained its robust replication fitness.
We, therefore, asked if the dimerization of the PR of HIV 8MIX P51 was blocked by DRV, exploiting the FRET-based HIV expression system by using a pair of newly generated plasmids encoding a full-length molecular infectious HIV clone containing CFP-or YFP-tagged PR with all 14 amino acid substitutions. As shown in Fig. 6 , DRV significantly blocked the dimerization of the wild-type PR of HIV NL4-3 at concentrations of 0.1 and 1 M. However, DRV failed to block the dimerization of the PR of HIV 8MIX P51 at 0.1 M (P ϭ 0.42). These data suggested that all amino acid substitutions present in the PR of HIV 8MIX P51 or subsets of them were associated with the HIV 8MIX P51 strain's acquisition of DRV resistance. 
Effects of V32I, L33F, I54M/L, and/or I84V substitutions on HIV susceptibility to DRV and PR dimerization inhibition by DRV. When we examined the sequence of the PR-encoding gene in HIV 8MIX
P51 and three clinical HIV variants isolated from individuals with AIDS who did not respond to DRVcontaining antiviral regimens (Table 2 ) (33), four amino acid substitutions (V32I, L33F, I54M, and I84V) were found to be mostly in common and thought to be relatively unique in such DRV-resistant HIV variants. The locations of the four amino acid substitutions are illustrated in Fig. 7A . This notion was further confirmed when we examined reports by others (9, 24, 33, 38) regarding the sequence of the PR-encoding region of DRV-resistant variants, as illustrated in Table 2 . We consequently examined whether the notion described above was plausible by incorporating one of the four amino acid substitutions or subsets of them.
When we introduced each of the four substitutions into the wild-type strain, HIV NL4-3 , there was no increase observed in the EC 50 s of DRV against such infectious recombinant clones, HIV NL4-3 (WT) 0 0 3 3 Ϯ 9.9 955 Ϯ 9. a Amino acid substitutions identified in the protease-encoding region of HIV are shown. The amino acid substitutions shown in the second row from the bottom were reported by De Meyer et al. (9) and Mitsuya et al. (33) . Those in the bottom row were reported by Van Marck et al. (38) and were reported to have the greatest impact on HIV-1 resistance to DRV. Those for HIV 8MIX
P51
were reported by Koh et al. (24) .
b Three infectious clones ( rCL HIV F16 , rCL HIV T45 , and rCL HIV T48 ) were derived from clinical strains isolated from patients who failed to respond to DRVcontaining regimens. with resistance ranging from 0.07-to 1.0-fold, as shown in Table 3 . Introduction of the combinations of two or three amino acid substitutions did not increase the EC 50 s of DRV against such clones either, with resistance ranging from 0.09-to 0.9-fold. However, when we introduced all four amino acid substitutions (V32I, L33F, I54M, and I84V), into HIV NL4-3 , generating HIV NL4-3 V32I/L33F/I54M/I84V , the EC 50 of DRV against HIV NL4-3 V32I/L33F/I54M/I84V was as high as 0.64 Ϯ 0.02 M with resistance of 205-fold (Table 3 ). These data suggested that the four amino acid substitutions are associated with the high-level resistance to DRV seen in HIV 8MIX P51 . We next examined the effects of one of the four amino acid substitutions or subsets of them on PR dimerization inhibition by DRV using the FRET-based HIV expression assay. Figure 7B shows that each single mutation of the four mutations allowed PR to undergo dimerization, and 1.0 M DRV effectively blocked the dimerization (P values ranging from 3.4EϪ07 to 0.0026). We next determined the effects of various combinations of the four amino acid mutations on dimerization inhibition by DRV (Fig. 7C) . Two mutations such as V32I and I84V still allowed PR to undergo dimerization, and DRV effectively blocked the dimerization at 0.1 and 1 M. When combinations of three amino acid substitutions such as V32I, L33F, and I84V and V32I, L33F, and I54M were introduced, the mean CFP A/B ratios were close to 1.0, the threshold for indication of the occurrence of dimerization, with 0.99 and 0.98, respectively, in the absence of DRV, suggesting that possibly such groups of three substitutions somewhat compromised PR dimerization, although DRV still significantly blocked the dimerization at 0.1 and 1 M, giving mean ratios ranging from 0.75 to 0.87. PR dimerization still occurred with all four substitutions, giving a mean CFP A/B ratio of 1.11; however, 0.1 M DRV clearly failed the dimerization, giving a ratio of 1.16 (P ϭ 0.3), while 1.0 M DRV blocked dimerization (P ϭ 0.00000073) (Fig. 7C) .
V82I, not V82A, contributes to the loss of DRV's activity to inhibit PR dimerization. Since V82A and V82I were seen in rCL HIV T48 and HIV 8MIX P51 , respectively (Table 2) , we examined whether V82A and V82I had effects on the loss of DRV's protease dimerization inhibition activity. Figure 8 shows that with V82A alone, PR dimerization occurred and 1 M DRV effectively blocked the dimerization. When V82A was combined with the three amino acid substitutions V32I, L33F, and I54M, PR dimerization still occurred, which DRV effectively blocked at both 0.1 and 1 M, suggesting that V82A substitution plays no significant role in conferring on HIV reduced sensitivity to the PR dimerization inhibition by DRV. We also examined the effects of the V82I substitution, which was identified in HIV 8MIX
, with or without the three amino acid substitutions, on inhibition of PR dimerization by DRV. Interestingly, the four combined amino acid substitutions V32I, L33F, I54M, and V82I abrogated DRV's PR dimerization inhibition activity at (Fig. 8) , strongly suggesting that V82I with other three amino acid substitutions contributes to the loss of DRV's activity to inhibit PR dimerization.
DISCUSSION
In the FRET-based HIV expression assay we previously reported, YFP-or CFP-containing PR should be initially expressed as a part of Pr160 gag-pol polyprotein, and it was assumed that PDIs block the dimerization of PR monomer subunit within the polyprotein. In the present study, we examined whether one of the PDIs, DRV, blocked the dimerization of HIV PR expressed as a single protease molecule. As expected, DRV effectively blocked the dimerization (Fig. 2B) , indicating that PDIs can block the dimerization of the PR monomers in the form of polyprotein as well as after autolysis (30, 31) . The dimerization of two identical PR monomers is required for the acquisition of PR catalytic activity (28, 40) , and the failure of PR dimerization should result in the loss of viral replication or compromised viral replication.
In our previous study (26) and in the present study, we demonstrated that a single amino acid substitution, such as I3A, L5A, R8Q, L24A, T26A, D29N, R87K, T96A, L97A, or F99A, effectively disrupts PR dimerization, as examined in the FRET-based HIV expression assay. In the present work, we constructed plasmids containing HIV NL4-3 -based recombinant clones with one of those amino acid substitutions and examined if such clones replicated in MT-4 cells. To this end, we attempted to propagate such recombinant clones in MT-4 cells using the supernatants obtained through transfection of 293T cells; however, all clones failed to replicate (Fig. 4B) . In contrast, similarly generated recombinant clones containing a single amino acid substitution such as P1A, Q2A, T4A, D30N, and N98A (26), none of which disrupted PR dimerization, as examined with the FRET-based HIV expression assay (26) , continued to replicate in MT-4 cells (Fig. 4B) . These data further confirmed the validity of the results obtained in the FRET-based HIV expression assay.
It is of note that HIV-1 protease containing A28S has virtually no enzymatic activity, as previously published by Hong et al. (20) , and as expected, recombinant HIV-1 NL4-3 with A28S (HIV NL4-3 A28S ) was totally replication incompetent, as shown in Fig. 4B . The D25A substitution is also known to render HIV-1 protease virtually enzymatically inactive; however, that substitution does not disrupt the dimerization of D25A protease as we previously published (26) . Yet, 1 M DRV clearly blocks the dimerization of D25A protease (Fig. 3A) , suggesting that D25 is not significantly associated with the putative DRV binding site in monomer subunit. These observations have led us to conclude that A28 is likely involved directly or indirectly in binding of DRV to the protease monomer subunit.
In recent clinical studies, a set of mutations, including V32I, L33F, I47V, I54L, and L89V has been identified in HIV strains isolated from patients failing DRV-containing regimens and has been associated with a diminished virological response to a regimen containing DRV boosted with ritonavir (DRV/r) (9, 33) . More recently, Van Marck et al. reported that a set of amino acid substitutions (V32I, I50V, I54L/M, L76V, and V82F) in the PR-encoding region of HIV might be associated with the failure of HIV-1 infected individuals receiving DRVcontaining antiviral regimens (38) . We have recently selected a highly DRV-resistant HIV variant (HIV 8MIX P51 ) by using a mixture of eight highly multi-PI-resistant (but DRV-sensitive) clinical HIV strains, isolated from those who had received various PIs and failed to respond to PI (not DRV)-containing regimens, by propagating the mixture in the presence of increasing concentrations of DRV in phytohemagglutinin-activated peripheral blood mononuclear cells (PHA-PBMCs) followed by MT-4 cells. HIV 8MIX P51 proved to have an EC 50 of DRV ϳ333-fold greater than that against a wild-type HIV strain. HIV 8MIX P51 was highly resistant to amprenavir, indinavir, nelfinavir, ritonavir, lopinavir, and atazanavir (all EC 50 s of Ͼ1 M) and moderately resistant to saquinavir and TPV (EC 50 s 33-and 18-fold greater, respectively) and replicated as rapidly as the wild-type HIV NL4-3 strain in the presence of 1 M DRV ( Table 1 ). The amino acid substitutions identified in HIV 8MIX P51 were L10I, I15V, K20R, L24I, V32I, L33F, M36I, M46L, I54M, L63P, K70Q, V82I, I84V, and L89M (24) . When we determined the amino acid sequences of three highly DRV-resistant clinical HIV strains, rCL HIV F16 , rCL HIV T45 , and rCL HIV T48 , which had EC 50 s of DRV of 0.30 M (97-fold), 0.33 M (105-fold), and 0.33 M (105-fold), respectively, we recognized that all three clinical isolates contained V32I, L33F, I54V, and I84V in common.
Thus, we hypothesized that PR dimerization inhibition by DRV might contribute to the antiviral activity of DRV and that the loss of PR dimerization inhibition by DRV might be associated with the decreased antiviral activity of DRV. When we introduced single, double, or triple amino acid substitutions of the four substitutions into pHIV-PR WT CFP and pHIV-PR WT YFP and cotransfected COS7 cells with such two plasmids, the dimerization of HIV-PR WT CFP and HIV-PR WT YFP clearly occurred in the absence of DRV, giving CFP A/B ratios ranging from 1.04 to 1.17 (Fig. 7B ). DRV at 1 M effectively blocked the dimerization of the PR containing a single one of the four amino acid substitutions (Fig. 7B) , giving average CFP A/B ratios ranging from 0.88 to 0.93. DRV at 0.1 and 1.0 M also blocked dimerization when two amino acid substitutions (V32I and I84V) and three substitutions (V32I, L33F, and I84V or V32I, L33F, and I54M) were introduced. However, when all four combined substitutions were introduced, DRV at 0.1 M failed to block the dimerization (Fig. 7C) , suggesting that the combination of the four substitutions compromised the activity of DRV to block the dimerization, presumably through altering the conformation of the monomer's putative binding site for DRV.
Considering that (i) the four amino acid substitutions in PR V32I, L33F, I54M, and I84V, were identified in the highly DRV-resistant HIV variant (HIV 8MIX P51 ) and various DRVresistant clinical HIV strains, such as rCL HIV F16 , rCL HIV T45 , and rCL HIV T48 , isolated from individuals failing DRV-containing regimens (9, 33) ; that (ii) multi-PI-resistant, but DRVsensitive HIV variants (24) do not contain the combination of the four substitutions; and (iii) that with the four substitutions combined, the activity of DRV to block PR dimerization is compromised, it is strongly suggested that the loss of PR dimerization activity is associated with the acquisition of resistance of HIV against DRV. More critically, the fact that the emergence of the four combined mutations is often seen in individuals failing DRV-containing regimens strongly suggests that the protein dimerization inhibition activity of DRV is in operation for the drug to exert its anti-HIV activity in a clinical setting. Our finding that four combined amino acid substitutions are required for the loss of PR dimerization inhibition activity of DRV should explain at least in part the reason why DRV has a high level of genetic barrier to HIV acquisition of DRV resistance. It is noteworthy that the crystallographic data of HIV PR monomer complexed with DRV are as yet unavailable; however, if the results of such structural analysis are obtained, it should help our understanding of the dynamics of the dimerization process of HIV PR, the mechanisms of the activity of DRV and other PDIs to block the dimerization, and the mechanisms of the emergence of HIV resistance against PDIs.
